Multidisciplinary Association for Psychedelic Studies

Maps was the sponsor of clinical trials studying investigational mdma-assisted therapy for ptsd and funder of regulatory activities supporting the proposed new drug application (nda) submission to the u.s. food and drug administration (fda). The second phase 3 trial that began in november 2020 continued to enroll participants at 13 sites in the u.s. and israel until april 2022. The trial enrolled participants with moderate-to-severe ptsd who were at least 18 years old. This phase 3 study protocol, along with the other trials in the clinical program, were developed in collaboration with the fda. The final data point was collected in november 2022. In 2023, the collected data was analyzed into a manuscript and sent to a peer-review journal.